Samuel Awuah, associate chemistry professor at UK, is developing gold-based compounds to be used in the treatment of diseases such as ulcerative colitis, traumatic brain injury and various forms of cancer.
The College of Pharmacy will host its 11th annual Therapeutics, Outcomes, Discovery & Delivery (TODD) Symposium from 8 a.m.–5 p.m. April 12, at the Lee T. Todd, Jr. Building.
The University of Kentucky Spinal Cord and Brain Injury Research Center (SCoBIRC) hosted a symposium last week featuring its first class of African American Research Training Scholars (AARTS).
Ultimately the study found that females who express the e4 allele of APOE have a negative response to intermittent hypoxia, indicating that treatment strategies may not be equally effective or beneficial for all individuals.
The National Institutes of Health award will fund ongoing research led by UK Neuroscience and Spinal Cord and Brain Injury Research Center (SCoBIRC) Professor Patrick Sullivan, Ph.D., who has studied the effects of the experimental drug MP201 on TBI.
A team of UK researchers have homed in on a protein, called RIT1, that may act as a master switch in the brain. A new five-year, $2.5 million grant from the National Institutes of Health will help them explore RIT1 as a possible target for treatments to counteract brain injury.
Case Western Reserve and UK's SCoBIRC were able to show the existence of a parallel neural network that could potentially restore diaphragm function after spinal cord injury. Perhaps more amazing is that this research is credited to a group of young scientists.
A pilot project spearheaded by UK College of Health Sciences researcher Carl Mattacola could be the first step towards developing a return-to-ride protocol for jockeys who suffer a concussion.
